Therefore, blockade of IL-17 has been shown to modulate the immunosuppressive tumor microenvironment and IL-17 may act as a determinant of differential response between chemotherapy alone and bimodal treatment strategies combined with chemotherapy and immunotherapy. This evidence concerns the gene IL17A and neoplasm.